AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28726512 — intervention group
Group type: EXPERIMENTAL
Intervention: Fucosylated HMOs
Number of subjects: 11
Study 28726512 — intervention group
Group type: EXPERIMENTAL
Intervention: Fucosylated/sialylated HMOs
Number of subjects: 11
Study 24965958 — intervention group
Group type: EXPERIMENTAL
Intervention: Body weight‐supported treadmill training
Number of subjects: 16
Study 24965958 — intervention group
Group type: COMPARATOR
Intervention: Body weight‐supported overground training
Number of subjects: 16
Study 24389401 — intervention group
Group type: EXPERIMENTAL
Intervention: ALND surgery
Number of subjects: 391
Study 24389401 — intervention group
Group type: EXPERIMENTAL
Intervention: SLNB surgery
Number of subjects: 391
Study 24389401 — intervention group
Group type: COMPARATOR
Intervention: Affected upper limb (ALND)
Number of subjects: 391
Study 24389401 — intervention group
Group type: COMPARATOR
Intervention: Control upper limb (unaffected)
Number of subjects: 391
Study 22639823 — intervention group
Group type: EXPERIMENTAL
Intervention: MSI/FM
Number of subjects: 43
Study 22639823 — intervention group
Group type: COMPARATOR
Intervention: RME/FM
Number of subjects: 43
Study 19129355 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep transthecal injection
Number of subjects: 15
Study 19129355 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous injection
Number of subjects: 15
Study 19129355 — intervention group
Group type: COMPARATOR
Intervention: Traditional transthecal injection
Number of subjects: 15
Study 17761317 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented tendon repair with plantaris tendon (group 1, n=16)
Number of subjects: 30
Study 17761317 — intervention group
Group type: COMPARATOR
Intervention: End-to-end suturing technique (group 2, n=14)
Number of subjects: 30
Study 17761317 — intervention group
Group type: COMPARATOR
Intervention: End-to-end suturing technique (group 2)
Number of subjects: 30
Study 17761317 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 30
Study 17761317 — intervention group
Group type: EXPERIMENTAL
Intervention: End-to-end suturing technique
Number of subjects: 30
Study 15218710 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate Simply White Clear Whitening Gel, three times daily, 30-second air-drying and 30 minutes without eating/drinking
Number of subjects: 120
Study 15218710 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate Simply White Clear Whitening Gel, four times daily, 30-second air-drying and 30 minutes without eating/drinking
Number of subjects: 120
Study 15218710 — intervention group
Group type: COMPARATOR
Intervention: Colgate Simply White Clear Whitening Gel, twice-daily, no air-drying, and 15 minutes without eating/drinking
Number of subjects: 120
Study 12210460 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal sonography
Number of subjects: 40
Study 9797080 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF 5 microg/kg per day subcutaneously starting 2 days after S‐HAM treatment
Number of subjects: 68
Study 9797080 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF
Number of subjects: 68
Study 7893090 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticarcillin/clavulanate
Number of subjects: 993
Study 7893090 — intervention group
Group type: COMPARATOR
Intervention: Clindamycin/gentamicin (without ampicillin)
Number of subjects: 993
Study 7893090 — intervention group
Group type: COMPARATOR
Intervention: Clindamycin/gentamicin (with ampicillin)
Number of subjects: 993
Study 2676877 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylpropanolamine (PPA) 37.5 mg immediate release
Number of subjects: 6
Study 371318 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 hours of preoperative antibiotic bowel preparation (gentamicin + vancomycin + mycostatin)
Number of subjects: 83
Study 371318 — intervention group
Group type: COMPARATOR
Intervention: 60 hours of preoperative antibiotic bowel preparation (gentamicin + vancomycin + mycostatin)
Number of subjects: 83
Study 371318 — intervention group
Group type: EXPERIMENTAL
Intervention: Long duration operations
Number of subjects: 83
Study 371318 — intervention group
Group type: EXPERIMENTAL
Intervention: Infected wounds
Number of subjects: 83
Study 31299919 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended hours haemodialysis (≥24 h/week)
Number of subjects: 200
Study 31299919 — intervention group
Group type: COMPARATOR
Intervention: Conventional haemodialysis (≤18 h/week)
Number of subjects: 200
Study 27859427 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrate HDF (heparin free)
Number of subjects: 10
Study 27859427 — intervention group
Group type: COMPARATOR
Intervention: Acetate HDF (routine dose of heparin)
Number of subjects: 10
Study 26383152 — intervention group
Group type: EXPERIMENTAL
Intervention: SB742457 (3 mg/d)
Number of subjects: 0
Study 26383152 — intervention group
Group type: EXPERIMENTAL
Intervention: SB742457 (15 mg/d)
Number of subjects: 0
Study 26383152 — intervention group
Group type: EXPERIMENTAL
Intervention: SB742457 (35 mg/d)
Number of subjects: 0
Study 26383152 — intervention group
Group type: EXPERIMENTAL
Intervention: SB742457 (3, 15, and 35 mg/d)
Number of subjects: 0
Study 24136111 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 h sitting interrupted with hourly, 8-min moderate-intensity cycling exercise bouts
Number of subjects: 11
Study 24136111 — intervention group
Group type: COMPARATOR
Intervention: 8 h prolonged sitting
Number of subjects: 11
Study 21214349 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration training (WBVT) applied using a vibratory platform (35 Hz, 5 mm peak to peak) for 60 seconds before eccentric exercise
Number of subjects: 32
Study 21214349 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vibration applied)
Number of subjects: 32
Study 18644546 — intervention group
Group type: EXPERIMENTAL
Intervention: SBHC users
Number of subjects: 579
Study 18644546 — intervention group
Group type: COMPARATOR
Intervention: Comparison school group
Number of subjects: 579
Study 16248986 — intervention group
Group type: COMPARATOR
Intervention: Aprepitant 160 mg
Number of subjects: 150
Study 16248986 — intervention group
Group type: COMPARATOR
Intervention: Aprepitant 80 mg
Number of subjects: 150
Study 16248986 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 20 mg
Number of subjects: 150
Study 16248986 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 13679549 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined diltiazem and aspirin/ticlopidine therapy
Number of subjects: 35
Study 13679549 — intervention group
Group type: COMPARATOR
Intervention: Aspirin/ticlopidine therapy alone
Number of subjects: 35
Study 10896877 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity intermittent bicycle training for 5 weeks
Number of subjects: 15
Study 10896877 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 15
Study 8967303 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate deficient transferrin (CDT)
Number of subjects: 0
Study 8967303 — intervention group
Group type: EXPERIMENTAL
Intervention: CDT/Tft ratio
Number of subjects: 0
Study 8967303 — intervention group
Group type: EXPERIMENTAL
Intervention: CDT and transferrin ratio
Number of subjects: 0
Study 8967303 — intervention group
Group type: EXPERIMENTAL
Intervention: PGA hepatic index
Number of subjects: 0
Study 1420752 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg b.d. plus Pirenzepine 50 mg b.d.
Number of subjects: 157
Study 1420752 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 150 mg b.d. plus Placebo (Control)
Number of subjects: 157
Study 3882739 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone treatment
Number of subjects: 1
Study 3882739 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1
Study 3882739 — intervention group
Group type: EXPERIMENTAL
Intervention: Exogenous GnRH
Number of subjects: 1
Study 3882739 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene
Number of subjects: 1
Study 30465187 — intervention group
Group type: EXPERIMENTAL
Intervention: Portal vein occlusion (PVO)
Number of subjects: 48
Study 30004615 — intervention group
Group type: EXPERIMENTAL
Intervention: Xenon-augmented sevoflurane anesthesia
Number of subjects: 40
Study 30004615 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane alone
Number of subjects: 40
Study 30004615 — intervention group
Group type: COMPARATOR
Intervention: Control group (no anesthesia)
Number of subjects: 40
Study 27252245 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthlines service (alongside usual care)
Number of subjects: 641
Study 27252245 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 641
Study 25183313 — intervention group
Group type: EXPERIMENTAL
Intervention: Permethrin-impregnated school uniforms (ISUs)
Number of subjects: 321
Study 22649265 — intervention group
Group type: EXPERIMENTAL
Intervention: 140 g/d of lipid-based nutrient supplements (LNS)
Number of subjects: 2121
Study 22649265 — intervention group
Group type: COMPARATOR
Intervention: No lipid-based nutrient supplements (LNS)
Number of subjects: 2121
Study 19177420 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrent laryngeal nerve (RLN) monitoring
Number of subjects: 1000
Study 19177420 — intervention group
Group type: COMPARATOR
Intervention: Standard protection (visualization)
Number of subjects: 1000
Study 17679566 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 60
Study 17679566 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimenhydrinate
Number of subjects: 60
Study 17679566 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 15551388 — intervention group
Group type: EXPERIMENTAL
Intervention: Valerian 300 mg
Number of subjects: 16
Study 15551388 — intervention group
Group type: EXPERIMENTAL
Intervention: Valerian 600 mg
Number of subjects: 16
Study 15551388 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 11431240 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular olanzapine, 10 mg
Number of subjects: 0
Study 11431240 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular haloperidol, 7.5 mg
Number of subjects: 0
Study 11431240 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular placebo
Number of subjects: 0
Study 9725662 — intervention group
Group type: EXPERIMENTAL
Intervention: 1‐monoglyceride
Number of subjects: 12
Study 9725662 — intervention group
Group type: EXPERIMENTAL
Intervention: triglyceride
Number of subjects: 12
Study 7884790 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine (5 mg to 15 mg once daily or 2.5 mg to 10 mg twice daily)
Number of subjects: 136
Study 7884790 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine with concomitant HCTZ (12.5 mg to 50 mg once daily)
Number of subjects: 136
Study 7884790 — intervention group
Group type: COMPARATOR
Intervention: Control group (HCTZ)
Number of subjects: 136
Study 3287901 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazemuls
Number of subjects: 120
Study 3287901 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 120
Study 3287901 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 120
Study 3287901 — intervention group
Group type: EXPERIMENTAL
Intervention: Consultant endoscopist
Number of subjects: 120
Study 3287901 — intervention group
Group type: EXPERIMENTAL
Intervention: Inexperienced resident
Number of subjects: 120
Study 3287901 — intervention group
Group type: EXPERIMENTAL
Intervention: Experienced resident
Number of subjects: 120
Study 30268189 — intervention group
Group type: EXPERIMENTAL
Intervention: Group O (surgical method O)
Number of subjects: 70
Study 30268189 — intervention group
Group type: COMPARATOR
Intervention: Group L (surgical method L)
Number of subjects: 70
Study 30268189 — intervention group
Group type: EXPERIMENTAL
Intervention: Group O
Number of subjects: 70
Study 30268189 — intervention group
Group type: COMPARATOR
Intervention: Group L
Number of subjects: 70
Study 27919638 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe 10mg + Atorvastatin 80mg
Number of subjects: 87
Study 27919638 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Atorvastatin 80mg
Number of subjects: 87
Study 26240491 — intervention group
Group type: EXPERIMENTAL
Intervention: Switching from cow's milk feeding to special formula or breast feeding in the infant group (n=8)
Number of subjects: 22
Study 26240491 — intervention group
Group type: EXPERIMENTAL
Intervention: Restriction of suspected foods and/or administration of ketotifen in the pEGE group (n=9)
Number of subjects: 22
Study 26240491 — intervention group
Group type: EXPERIMENTAL
Intervention: Restriction of suspected foods in both hEGE and pEGE groups
Number of subjects: 22
Study 26240491 — intervention group
Group type: COMPARATOR
Intervention: Comparison between infant group and child group
Number of subjects: 22
Study 23979954 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle change (ILS)
Number of subjects: 0
Study 23979954 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 850 mg
Number of subjects: 0
Study 23979954 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20351570 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-Hz right prefrontal rTMS
Number of subjects: 60
Study 20351570 — intervention group
Group type: COMPARATOR
Intervention: ECT
Number of subjects: 60
Study 17882913 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of cetirizine once per day
Number of subjects: 120
Study 17882913 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of zafirlukast once per day
Number of subjects: 120
Study 17882913 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of cafirlukast twice per day
Number of subjects: 120
Study 17882913 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 20 mg of zafirlukast and 10 mg of cetirizine once per day
Number of subjects: 120
Study 17882913 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 20 mg of zafirlukast twice per day and 10 mg cetirizine once per day
Number of subjects: 120
Study 17882913 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 120
Study 17882913 — intervention group
Group type: COMPARATOR
Intervention: Low-dose anti-LT
Number of subjects: 120
Study 17882913 — intervention group
Group type: COMPARATOR
Intervention: Antihistamine alone
Number of subjects: 120
Study 17882913 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-LT treated groups
Number of subjects: 120
Study 17882913 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose anti-LT or combination of low-dose anti-LT and antihistamine
Number of subjects: 120
Study 17882913 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-LT
Number of subjects: 120
Study 15215154 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intramuscular corticosteroids (triamcinolone)
Number of subjects: 22
Study 15215154 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 11577957 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP + TCF (local tetracycline fiber in pockets with PD > or =5 mm)
Number of subjects: 30
Study 11577957 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP + AUG (amoxicillin/clavulanic acid 500 mg tid)
Number of subjects: 30
Study 11577957 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP + TCF (local tetracycline fiber)
Number of subjects: 30
Study 11577957 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP + AUG (amoxicillin/clavulanic acid)
Number of subjects: 30
Study 9835240 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 67
Study 9835240 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 67
Study 7927581 — intervention group
Group type: EXPERIMENTAL
Intervention: Phototherapy with TcBI estimation on the forehead (uncovered group)
Number of subjects: 100
Study 7927581 — intervention group
Group type: COMPARATOR
Intervention: Phototherapy with TcBI estimation on the forehead (covered group)
Number of subjects: 100
Study 2600826 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine polacrilex gum (2 or 4 mg)
Number of subjects: 15
Study 2600826 — intervention group
Group type: COMPARATOR
Intervention: Placebo gum
Number of subjects: 15
Study 2600826 — intervention group
Group type: COMPARATOR
Intervention: Tobacco abstinence (no nicotine for 10 days)
Number of subjects: 15
Study 2600826 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine polacrilex (4 mg)
Number of subjects: 15
Study 45483 — intervention group
Group type: EXPERIMENTAL
Intervention: Disodium cromoglycate
Number of subjects: 4
Study 45483 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 4
Study 45483 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiazinamium
Number of subjects: 4
Study 45483 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 4
Study 29481425 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% human albumin and crystalloids
Number of subjects: 958
Study 29481425 — intervention group
Group type: COMPARATOR
Intervention: Crystalloid solutions alone
Number of subjects: 958
Study 28284926 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextrose infusion (0.9% saline control)
Number of subjects: 8
Study 28284926 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcholine infusion (both arms)
Number of subjects: 8
Study 28284926 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextrose infusion (after reperfusion)
Number of subjects: 8
Study 28284926 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (control)
Number of subjects: 8
Study 26330582 — intervention group
Group type: EXPERIMENTAL
Intervention: Resurfacing hip arthroplasty (RHA)
Number of subjects: 36
Study 26330582 — intervention group
Group type: COMPARATOR
Intervention: Metal-on-metal total hip arthroplasty (MoM THA)
Number of subjects: 36
Study 26330582 — intervention group
Group type: COMPARATOR
Intervention: Ceramic-on-polyethylene total hip arthroplasty (CoP THA)
Number of subjects: 36
Study 24495641 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of a mixture of 65% nitrous oxide and oxygen during dressing change
Number of subjects: 240
Study 24495641 — intervention group
Group type: COMPARATOR
Intervention: Inhalation of oxygen during dressing change
Number of subjects: 240
Study 21626011 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine concentration of 8 mg/mL
Number of subjects: 102
Study 21626011 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine concentration of 5 mg/mL
Number of subjects: 102
Study 21626011 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine concentration of 3.3 mg/mL
Number of subjects: 102
Study 18636531 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Patient Examinations (VPEs)
Number of subjects: 82
Study 18636531 — intervention group
Group type: COMPARATOR
Intervention: Control group (no supplemental CE instruction)
Number of subjects: 82
Study 16515571 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidoxorubicin 120 mg/sqm for 4 months
Number of subjects: 138
Study 16515571 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 138
Study 15184237 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy modified for adolescents (IPT-A)
Number of subjects: 63
Study 15184237 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 63
Study 11434168 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with chronic glomerulonephritis (GN)
Number of subjects: 60
Study 11434168 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with GN and syndrome nephroticum
Number of subjects: 60
Study 11434168 — intervention group
Group type: COMPARATOR
Intervention: Control group (15 healthy children)
Number of subjects: 60
Study 9481146 — intervention group
Group type: EXPERIMENTAL
Intervention: EuroQoL questionnaire
Number of subjects: 214
Study 8021765 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine (60 to 180 mg/m2 per dose) given orally every 6 hours
Number of subjects: 54
Study 8021765 — intervention group
Group type: EXPERIMENTAL
Intervention: Didanosine (60 to 180 mg/m2 per dose) given every 12 hours
Number of subjects: 54
Study 8021765 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of zidovudine and didanosine
Number of subjects: 54
Study 8021765 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine and didanosine after 4 and 12 weeks of treatment
Number of subjects: 54
Study 8021765 — intervention group
Group type: EXPERIMENTAL
Intervention: Didanosine
Number of subjects: 54
Study 2723711 — intervention group
Group type: EXPERIMENTAL
Intervention: Alarm algorithm for ventilator monitoring
Number of subjects: 2
Study 810269 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% solution of sodium cromoglycate (SCG), administered as a fine spray six times a day for 4 weeks, approximately 31-32 mg daily.
Number of subjects: 0
Study 810269 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution, administered as a fine spray six times a day for 4 weeks.
Number of subjects: 0
Study 30107621 — intervention group
Group type: EXPERIMENTAL
Intervention: Game decision aid
Number of subjects: 73
Study 30107621 — intervention group
Group type: COMPARATOR
Intervention: Brochure (Control)
Number of subjects: 73
Study 29232379 — intervention group
Group type: COMPARATOR
Intervention: sufentanil 0.1 μg/kg (group S)
Number of subjects: 240
Study 29232379 — intervention group
Group type: EXPERIMENTAL
Intervention: nalbuphine 0.1 mg/kg (group N1)
Number of subjects: 240
Study 29232379 — intervention group
Group type: EXPERIMENTAL
Intervention: nalbuphine 0.15 mg/kg (group N2)
Number of subjects: 240
Study 29232379 — intervention group
Group type: EXPERIMENTAL
Intervention: nalbuphine 0.2 mg/kg (group N3)
Number of subjects: 240
Study 29232379 — intervention group
Group type: EXPERIMENTAL
Intervention: nalbuphine groups (N1, N2, N3)
Number of subjects: 240
Study 26225794 — intervention group
Group type: EXPERIMENTAL
Intervention: 5α-reductase inhibitors (5αRIs) for 3 years after TURP
Number of subjects: 87
Study 26225794 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 87
Study 26225794 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutasteride
Number of subjects: 87
Study 26225794 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 23072267 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional therapy plus aromatherapy (rose essential oil)
Number of subjects: 80
Study 23072267 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy plus placebo (physiological serum, 0.9% NaCl)
Number of subjects: 80